Lyon, France
Joined February 2012
- Tweets4.6K
- Following758
- Followers374
- Likes414
Thomas Pierret 🫁 retweeted
Savo + Osi >>> Osi
In 1L stage IV, EGFRmut: Better PFS and remarkable 44.5 OS for a poor prognosis population, with the cost of more MET-related side effects.
High attrition to find MET-IHC3+. Wondering how this data compares to this subset of patients in the MARIPOSA trial. #ESMO26 #LCSM
Thomas Pierret 🫁 retweeted
ESMO 2026 | A cautionary tale for immunotherapy de-escalation!
MOIO Trial (LBA10) – Phase III non-inferiority trial testing 3-monthly immunotherapy vs standard dosing in responding patients with advanced/metastatic cancer.
📊 Key results (N=308):
• Median PFS: 21.9 vs 25 months (reduced vs standard; HR 1.35)
• Risk of death: HR 2.0 (95% CI 1.1–3.9; p=0.0143) ⚠️
• PFS HR in urothelial cancer: 2.9
• Grade 3–4 immune-related AEs: 9.5% vs 10.5%
❌ Non-inferiority NOT demonstrated.
❌ No meaningful safety advantage.
⚠️ Signal of inferior survival with reduced-frequency IO.
💡 Take-home: Less frequent immunotherapy is not necessarily equally effective!
Important: These are interim results with relatively small numbers and heterogeneous tumour types.
#ESMO26 #MOIO #Immunotherapy #Oncology @OncoAlert @myESMO
Thomas Pierret 🫁 retweeted
Pembro monotherapy still has a role in selected pts (borderline ECOG PS or where a pt does not want to do chemo) but the control arm did not underperform. The final median PFS for Pembro mono in KN024 was only 3 weeks less than the control arm performance in PERSEE was it not?
Thomas Pierret 🫁 retweeted
Brilliant discussion from Dr. @BenjaminBesseMD at #ESMO26 on the Krascendo 1 study of divarasib vs sotorasib/adagrasib. Rightly points out lack of crossover in a study with a PFS endpoint as unjust. Excellent points all around. #ESMOAmbassadors
Thomas Pierret 🫁 retweeted
No information by molecular subtypes (eg KRAS mut) or elderly patients where combination may be not necessary or even detrimental because of side effects.
Thomas Pierret 🫁 retweeted
Impressive results Academic III PERSEE #ESMO26 @Annals_Oncology First positive random trial adding chemo to pembro in PD-L1 ≥50% NSCLC:
🔹 PFS: 16.1 vs 6.9 mo HR 0.56
🔹 OS: 50.2 vs 29.9 mo HR 0.77, NS
🔹 G≥3 TRAEs: 54% vs 19%
Outstanding discussion Prof. Levy
@benlevylungdoc.
Thomas Pierret 🫁 retweeted
‼️ In first line treatment of advanced PD-L1 ≥50% NSCLC, PERSEE demonstrates a significant improvement of PFS with pembro-CT compared to pembro monotherapy regardless of PDL1 level of (over)expression. Practise changing trial. @myESMO @OncoAlert #ESMO26 👏👏👏 @decroisette
Thomas Pierret 🫁 retweeted
Randomised phase 3 Persée study presented at #ESMO26 this morning
➡️ chemotherapy and Pembrolizumab improved OS when compared with Pembro alone in patients with local advanced NSCLC with PD-L1 ≥50%
Thomas Pierret 🫁 retweeted
Off the rousing #ESMO26 oral presentation from Dr. @decroisette, the phase III PERSEE trial with simultaneous publication @Annals_Oncology. Combination of chemotherapy + pembrolizumab superior to pembro in PDL1 high NSCLC: PFS 16.1 vs 6.9m, HR 0.56!
annalsofoncology.org/article…
Thomas Pierret 🫁 retweeted
🆙#ESMO26 Proffered Paper I: #LCSM Mets
🔥OptiTROP-Lung04: Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) Versus Platinum-Based Chemotherapy in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) After Progression on EGFR-TKI: Phase III Study
🎙️Dr. Wenfeng Fang
🔢LBA67
🎯Sustained OS Benefit at 32.3-Mo Follow-Up
🎯Median OS 25.9 vs 17.4mo (HR 0.69; n=376)
🎯24-Mo OS 54.1% vs 37.2%
☑️NCT05870319
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
🆙 #ESMO26 Proffered Paper I: #LCSM Mets
🔥OptiTROP-Lung04: Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) Versus Platinum-Based Chemotherapy in EGFR-Mutated NSCLC After Progression on EGFR-TKI
🎙️Dr. Li Zhang
🔢LBA67
☑️NCT05870319
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
Thomas Pierret 🫁 retweeted
#ESMO26 | SAFFRON | Presidential Session-2
In EGFR-mutant, MET-overexpressed/amplified advanced NSCLC after osimertinib:
Osimertinib + savolitinib vs platinum-pemetrexed:
🔹 PFS: 7.6 vs 5.4 mo (HR 0.55)
🔹 OS: 17.8 vs 12.9 mo(HR 0.68)
Thomas Pierret 🫁 retweeted
#ESMO26 | Presidential Session 2 – KRASCENDO-1
Divarasib vs sotorasib/adagrasib in previously treated KRAS G12C-mutant aNSCLC
- PFS: 9.8 vs 5.7 mo
- OS: 17.7 vs 12.0 mo
- ORR: 58.4% vs 32.3%
- G 3–4 TRAEs: 43.1% vs 51.5%
🔹️Control arm: 156 patients sotorasib and 15 adagrasib
Thomas Pierret 🫁 retweeted
#ESMO26 | OptiTROP-Lung06
PD-L1 <1% non-sq NSCLC:
Sac-TMT + pembro vs platinum/pem + pembro
🔹 PFS: 15 vs 5.7 mo (HR 0.49)
🔹 DoR: 13.6 vs 6.8 mo
🔹 OS: HR 0.58 (immature)
🔹 ≥G3 AEs: 47.6% vs 60.6%
Strong results vs contemporary chemo-IO.
Thomas Pierret 🫁 retweeted
#ESMO26 Dr. Martin Sebastian presents PACE-LUNG: phase II study of osimertinib monotherapy for EGFR NSCLC with ctDNA at 3w and if positive, add 4 cycles of chemotherapy. 72/255 were ctDNA positive at 3w. mPFS 17.8m and OS 31.5m from start of osi - no comparator but encouraging.
Thomas Pierret 🫁 retweeted
DeLLphi-305 - tarlatamab added to durvalumab after initial chemo-immunotherapy for small lung cancer essentially doubles survival. Hope for all cancers here, if the right target & treatment modality can be refined. Unquestionably a new standard for this disease. #ESMO2026
Thomas Pierret 🫁 retweeted
🆙#ESMO26 Rapid Oral: #LCSM Non-Mets
🔥iTHYM: Ivonescimab Plus Chemotherapy as First-Line Treatment in Recurrent/Metastatic Thymic Carcinoma: Results From the Phase II Study
🎙️Dr. Xue Hou
🔢4156RO
🎯Met Primary Endpoint: 6-Mo PFS Rate (All 19 Evaluable Pts Progression-Free)
🎯ORR 83.3%, DCR 100% (n=24)
☑️NCT06750952
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
🆙 #ESMO26 Rapid Oral: #LCSM Non-Mets, others
🔥iTHYM: Ivonescimab Plus Chemotherapy as First-Line Treatment in Recurrent/Metastatic Thymic Carcinoma: Interim Results From the Phase II Study
🎙️Dr. Xue Hou
🔢4156RO
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
Thomas Pierret 🫁 retweeted
🫁 PD-L1 ≥50% has long supported pembrolizumab monotherapy — but PERSEE asks whether some of these patients should receive more upfront.
@OncoAlert
At #ESMO26, phase III PERSEE compared pembrolizumab + platinum-based chemotherapy versus pembrolizumab alone in first-line advanced #NSCLC with PD-L1 ≥50%.
📊 n=321
➡️ Median PFS: 16.1 vs 6.9 months
HR 0.56 (0.43–0.74), p<0.001
➡️ Median OS: 50.2 vs 29.9 months
HR 0.77 (0.57–1.05)
➡️ ORR: 77.5% vs 50.3%
But the trade-off is substantial:
⚠️ Grade ≥3 TRAEs: 53.8% vs 19.3%
🎯 Why this matters: PD-L1 ≥50% may not be enough, by itself, to decide between pembrolizumab alone and chemo-immunotherapy.
For me, the real clinical question is now:
Which PD-L1–high patients need the deeper and faster disease control of chemotherapy upfront — and which can safely avoid the added toxicity?
That is where tumor burden, symptoms, pace of disease, comorbidities and better biomarkers will matter most.
Excellent work from @decroisette @BenjaminBesseMD @LGreillier @C_Ricordel @FGuisier and the PERSEE investigators.
Pinging @christine_lovly @GlopesMd @DrSanjayPopat @StephenVLiu @jillfeldman4 @CharuAggarwalMD @peters_solange @BRicciutiMD @VanitaNoronha @JordiRemon
#OncoAlert #ESMO26 #LungCancer #NSCLC #Immunotherapy #PDL1 #PrecisionOncology
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%: PERSEE Phase 3 Trial (GFPC 01-2020)
@decroisette
@BenjaminBesseMD
@LGreillier
@C_Ricordel
@FGuisier
🫁 Phase 3, open-label (n=321): pembrolizumab + platinum-based chemotherapy vs pembrolizumab alone, first-line advanced NSCLC with PD-L1 ≥50%. Primary endpoint: PFS by blinded central review.
➡️ Median PFS 16.1 vs 6.9 mo; HR 0.56 (0.43–0.74); p<0.001
➡️ Median OS 50.2 vs 29.9 mo; HR 0.77 (0.57–1.05); ORR 77.5% vs 50.3%
➡️ Grade ≥3 TRAEs 53.8% vs 19.3%
✅ Pembrolizumab-chemotherapy significantly improved PFS vs pembrolizumab monotherapy and may help refine treatment selection. #NSCLC #LungCancer
🎙️ Chantal Decroisette
👥 Renaud Descourt · Christos Chouaid · Maurice Pérol · Benjamin Besse · Laurent Greillier · Olivier Bylicki · Charles Ricordel · Florian Guisier · Radj Gervais · Roland Schott · Jean-Bernard Auliac · Gilles Robinet
(4Sight Made from Abstracts publicly available at the ESMO website)
Pinging our OncoAlert Lung Cancer Faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran
Thomas Pierret 🫁 retweeted
#ESMO26
🔥Stay tuned for the highly anticipated results of PERSEE (@myGFPC 01-2020), our phase III trial evaluating pembrolizumab ± chemotherapy as first-line treatment for aNSCLC PD-L1 ≥50%.
🎙️ Presented by @decroisette
📅 Sunday, Oct 25
📍 Alicante Auditorium – Hall 6
Thomas Pierret 🫁 retweeted
#ESMO26 | PERSEE – Phase III
In advanced NSCLC with PD-L1 ≥50%, adding chemotherapy to pembrolizumab improved median PFS from 6.9 to 16.1 months (HR 0.56). The numerical OS difference was notable (50.2 vs 29.9 months; HR 0.77), but not statistically significant. However, we should remember that OS was not the primary endpoint!
Grade ≥3 toxicity: 53.8% vs 19.3%.
I think adding chemotherapy provides benefit, but at the cost of increased toxicity. We need to better identify the patients for whom this toxicity is worth it.
